HC Wainwright began coverage on shares of Palatin Technologies (NASDAQ:PTN – Free Report) in a report released on Friday, MarketBeat reports. The firm issued a buy rating and a $12.00 price objective on the stock. HC Wainwright also issued estimates for Palatin Technologies’ Q1 2027 earnings at ($0.32) EPS, Q2 2027 earnings at ($0.33) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.49) EPS and FY2027 earnings at ($1.50) EPS.
Palatin Technologies Price Performance
NASDAQ:PTN traded up $0.56 during trading hours on Friday, reaching $6.27. The stock had a trading volume of 33,724 shares, compared to its average volume of 34,163. The company has a market capitalization of $11.16 million, a P/E ratio of -78.38 and a beta of 0.75. Palatin Technologies has a 12-month low of $4.51 and a 12-month high of $31.00.
Palatin Technologies Company Profile
Palatin Technologies is a biopharmaceutical company that develops peptide-based medicines designed to act on specific receptors. Its research has focused primarily on the melanocortin system, which is involved in a range of biological functions and potential therapeutic applications.
The company’s commercial product is Vyleesi (bremelanotide), an injectable prescription medicine approved in the United States to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Further Reading
- Five stocks we like better than Palatin Technologies
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
